Form 4: Intellia CFO Receives Significant Equity Grants

Intellia Therapeutics' EVP and CFO, Edward J. Dulac III, was granted 61,280 restricted stock units and 87,543 stock options on March 1, 2026.

Summary

• Edward J. Dulac III, Executive Vice President and Chief Financial Officer of Intellia Therapeutics, Inc. (NTLA), received equity grants.
• On March 1, 2026, Dulac was granted 61,280 restricted stock units (RSUs) of common stock, representing a contingent right to receive one share of Intellia common stock for each unit.
• Additionally, Dulac was granted 87,543 stock options with an exercise price of $13.78.
• The stock options have a specific vesting schedule: 33% will vest on January 1, 2027, and the remaining 67% will vest in 24 substantially equal monthly installments thereafter.
• The granted stock options are set to expire on February 29, 2036.
• Following these transactions, Dulac beneficially owns 160,963 shares of common stock directly and 87,543 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting the company's commitment to retaining key executive talent and aligning management's interests with long-term shareholder value through equity incentives.

Positives

• The grant of 61,280 restricted stock units and 87,543 stock options to a key executive like the CFO indicates strong alignment of management's interests with long-term shareholder value.
• Equity grants are a common and effective incentive for executive retention and performance in the biotechnology sector.
• The multi-year vesting schedule for the stock options provides a long-term incentive for the CFO to remain with the company and contribute to its sustained success.

Future Outlook

The equity grants, particularly the stock options with their multi-year vesting schedule extending to January 2027 and beyond, indicate a long-term commitment from the company to retain and incentivize its Chief Financial Officer. This structure aligns the executive's future financial interests with the company's long-term performance and strategic goals.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units and stock options, are standard components of executive compensation packages in the highly competitive biotechnology and pharmaceutical industries. These grants are crucial for attracting and retaining top talent, especially in companies like Intellia Therapeutics, which operate in the innovative and high-risk field of gene editing. The structure of these grants, with multi-year vesting, is designed to align executive incentives with long-term shareholder value creation, a common practice across the sector.

Comparison to Industry Standards

• The grant of RSUs and stock options to a CFO is a standard practice in the biotechnology industry, comparable to compensation structures seen at companies like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT), which also utilize equity to incentivize key executives.
• The vesting schedule, with a portion vesting after one year and the remainder over subsequent months, is typical for executive retention and performance alignment in high-growth sectors.
• The exercise price of $13.78 for the stock options would typically be evaluated against NTLA's stock price on the grant date (March 1, 2026) to determine if it was an 'at-the-money' or 'in-the-money' grant, a common practice for performance-based incentives.

Related Party Transactions

• The equity grants to Edward J. Dulac III, an executive officer of Intellia Therapeutics, Inc., constitute a related party transaction as part of his compensation package.

Stakeholder Impact

• Shareholders: The grants align the CFO's financial interests with long-term shareholder value, potentially leading to more focused management decisions aimed at increasing stock price. However, they also represent potential future dilution upon exercise/vesting.
• Employees: May signal stability in leadership and a commitment to executive retention, which can positively influence overall employee morale.
• Management: Provides significant long-term incentives and compensation, encouraging continued dedication and performance.

Next Steps

• The granted stock options will begin vesting, with 33% on January 1, 2027, and the remaining 67% in 24 substantially equal monthly installments thereafter.
• The restricted stock units will vest according to their specific terms, which are not fully detailed beyond being a 'contingent right to receive one share'.

Key Dates

Recommendation

While the equity grants to the CFO are a positive signal for executive retention and alignment with shareholder interests, this Form 4 filing alone does not provide sufficient information on the company's operational performance, financial health, or strategic direction to warrant a 'buy' or 'sell' recommendation. It is an expected part of executive compensation. Investors should 'hold' and await more comprehensive financial reports and business updates to make a more informed decision.

Keywords

Intellia Therapeutics, NTLA, Edward J. Dulac III, CFO, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Insider Transaction, Executive Compensation, Biotechnology, SEC Form 4